Is Semaglutide a GLP-1? What the Class Means

Is semaglutide a GLP-1? Yes. More precisely, semaglutide is a GLP-1 receptor agonist: an engineered peptide medication that activates the receptor used by the natural hormone glucagon-like peptide-1. It is not the hormone itself. In everyday conversation, people often say "a GLP-1" when they mean a medication in this class.

That classification puts semaglutide in the same broad family as exenatide, liraglutide and dulaglutide. Tirzepatide overlaps with the family but activates a second receptor too, so it is described as a dual GIP/GLP-1 receptor agonist.

Why is semaglutide a GLP-1 receptor agonist?

A drug class is usually named for a shared biological target. Semaglutide binds to and activates the GLP-1 receptor, so it belongs to the GLP-1 receptor agonist class. "Agonist" simply means that it turns on the receptor rather than blocking it.

That answer is about classification, not a complete account of the downstream biology. GLP-1 receptor signaling affects glucose-dependent insulin release, glucagon, gastric emptying and appetite. The full sequence is covered in how semaglutide works.

The molecule was deliberately designed as a longer-acting GLP-1 analogue. The original discovery paper described amino-acid changes and a fatty-diacid side chain that extended its activity enough for weekly injection (Lau et al., Journal of Medicinal Chemistry, 2015). That design is why semaglutide can resemble the hormone's signal without being identical to the hormone.

GLP-1 can mean a hormone or a drug class

The natural GLP-1 hormone is an incretin released from the gut after food arrives. Its signal is brief. The body breaks native GLP-1 down quickly.

A GLP-1 receptor agonist is a medication built to activate the same receptor and remain active much longer. That difference matters: semaglutide is not a dose of naturally occurring GLP-1. It is an analogue engineered for a practical treatment interval. In a randomized pharmacokinetic study, subcutaneous semaglutide had a half-life of about one week, consistent with weekly administration (Ikushima et al., Advances in Therapy, 2018).

The phrase "GLP-1 medication" is therefore useful shorthand, but "GLP-1 receptor agonist" is the more exact name.

Which medicines are in the GLP-1 family?

Several medications activate the GLP-1 receptor, but they are not interchangeable. Their molecular structures, labeled uses, formats and treatment rhythms differ.

The oral form does not place semaglutide in a different drug class. A phase 1 program found that the oral formulation's pharmacokinetics supported once-daily dosing (Granhall et al., Clinical Pharmacokinetics, 2019). Route and schedule describe how a product is used; receptor activity defines the class.

Tirzepatide is the important edge case. Its GLP-1 activity is real, but its GIP activity makes "dual agonist" the accurate label. The distinction—and why tirzepatide is also a peptide—is explained in is tirzepatide a peptide?.

Why semaglutide is also a peptide

"Peptide" and "GLP-1 receptor agonist" answer different questions. Peptide describes what semaglutide is made from: an engineered chain of amino acids. GLP-1 receptor agonist describes what target it activates. Both descriptions are correct at the same time.

That also explains why "peptide" is too broad to predict what a medication does. Insulin is a peptide. So are many hormones and signaling molecules with entirely different targets. The clinically useful question is not only whether a compound is a peptide, but which receptor it acts on and what evidence supports its prescribed use.

What this drug class shares—and what it does not

GLP-1 receptor agonists share a target, and gastrointestinal effects recur across the class. Nausea, diarrhea, vomiting and constipation are common examples, especially while treatment is being adjusted. In the head-to-head SUSTAIN 7 trial, gastrointestinal disorders were reported by 33% to 48% of participants across four semaglutide and dulaglutide groups (Pratley et al., The Lancet Diabetes & Endocrinology, 2018). Those arm-level results show a class pattern, not a forecast for one person. Semaglutide side effects covers the practical safety picture in detail.

Treatment frequency is not universal. Some products are taken daily, others weekly, and semaglutide itself exists in both weekly injectable and daily oral forms. The prescriber sets the formulation, dose and schedule; a class label does not supply an individual dosing plan.

Semaglutide products also carry a boxed warning about thyroid C-cell tumors. The current Wegovy prescribing information says the finding occurred in rodents and that its relevance to humans is unknown. It lists a personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2, as contraindications. Similar warnings appear on several long-acting products in the class, but the exact label still matters.

The compounded semaglutide distinction

Semaglutide dispensed through Promise is a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The FDA does not review compounded preparations for safety, effectiveness or quality before marketing, as its current GLP-1 compounding guidance explains. A compounded prescription is also not a generic version of a branded product.

The regulatory distinction does not change the pharmacologic classification: semaglutide remains a GLP-1 receptor agonist. It does change which finished product is being prescribed and what review that product has received. At Promise, a licensed provider reviews every request, may prescribe a compounded formulation when clinically appropriate, and may decline because not everyone qualifies; that decision is between the patient and the provider.

Knowing the class is a useful first filter. It tells you the receptor semaglutide activates, but not which formulation, schedule or risk profile fits a particular medical history. Those decisions belong in the clinical review.